Gilead Sciences, Inc. filed its 13F report for Q2 2026 on August 03, 2026. The portfolio totaled 1.65 B reflecting a -22.15% change from the prior quarter, spanning 5 assets. The top 10 holdings comprised 100.0% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 0 new positions and 1 complete exits.
Items:
Total Value:
| Issuer Name | Class | Value | Shares | Option Type |
|---|
Gilead Sciences submitted their Form 13F-HR for the Q2 2026 period on 08/03/2026. This was the only submission for the quarter.
In the Q2 2026 filing, Gilead Sciences reported a managed portfolio value of 1.65 B, consisting of 5 individual positions.
This page displays the raw filing documents. To see which stocks Gilead Sciences bought or sold during Q2 2026, please visit Gilead Sciences's Portfolio Analysis page.